Neuropore Therapies, Inc. has received a second grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) in support of its Toll-Like Receptor 2 (TLR2) antagonist program focused on modulating neuroinflammation and autophagy in Parkinson’s disease and other neurodegenerative diseases.
Report in Brain, describes findings supporting the hypothesis that NPT®100-18A reduces alpha-synuclein toxicity through a novel mechanism that involves displacing pathological alpha-synuclein from the membrane.
